Pharsight

Stendra generic

Stendra is an erectile dysfunction treatment drug owned by Metuchen Pharms. It contains the active ingredient avanafil and was first authorized for market use on April 27, 2012.

When will Stendra generic be available?

The generic version of Stendra is expected to be available after October 18, 2025. This is after the expiration of its last relevant patent, US6656935, on April 27, 2025.

Stendra uses

Stendra is used for the treatment of erectile dysfunction. Its effectiveness is attributed to avanafil, its active ingredient, which helps increase blood flow to the penis, thereby aiding erectile function.

Stendra patent expiration

Stendra holds two patents, with one already expired. The last patent, US6656935, titled 'Aromatic nitrogen-containing 6-membered cyclic compounds' will expire on April 27, 2025. Below are the details of the patent:

Stendra dosage

Want to ask something?